TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

50:1-26.
14A.49 Schuster FL et al. Opportunistic amoebae: prophylaxis and treatment. Drug Resist Updates 2004;7:
41-51.
14A.50 Schuster FL et al. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans
and animals. Int J Parasitol 2004;34:1001-27.
14A.51 Schuster FL et al. In vitro activity of miltefosine and voriconazole on clinical isolates of free-living
amebas: Balamuthia mandrillaris, Acanthamoeba spp. and Naegleria fowleri. J Eukaryot Microbiol
2006;53:121-6.
14A.52 Schuster FL et al. Under the radar: Balamuthia amebic encephalitis. Clin Infect Dis 2009;48:879-87.
14A.53 Matin A et al. Increasing importance of Balamuthia mandrillaris. Clin Microbiol Rev 2008;21:435-48.
14A.54 Jung S et al. Balamuthia mandrillaris meningoencephalitis in an immunocompetent patient. Arch Pathol
Lab Med 2004;128:466-8.
14A.55 Marciano-Cabral F et al. Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev
2003;16:273-307.
14A.56 Singhal T et al. Successful treatment of Acanthamoeba meningitis with combination oral antimicrobials.
Pediatr Infect Dis J 2001;20:623-7.
14A.57 Deetz TR et al. Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases.
Clin Infect Dis 2003;37:1304-12.
14A.58 Slater CA et al. Successful treatment of disseminated Acanthamoeba infection in an immuno-compromised
patient. N Engl J Med 1994;331:85-7.
14A.59 Kim JH et al. Effect of therapeutic chemical agents in vitro and on experimental meningoen-cephalitis
due to Naegleria fowleri. Antimicrob Agents Chemother 2008;52:4010-6.
14A.60 Vargas-Zepeda J et al. Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous
amphotericicn B, fluconazole and rifampicin. Arch Med Res 2005;36:83-6.
14A.61 Soltow SM et al. Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in
vitro and in a mouse model of primary amebic meningoencephalitis. Antimicrob Agents Chemother
2007;51:23-7.
14A.62 Gelman BB et al. Amoebic encephalitis due to Sappinia diploidea. J Am Med Assoc 2001;285:2450-
1.
14A.63 Wormser GP et al. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients
with Babesia microti infection. Clin Infect Dis 2010;50:381-6.
14A.64 Vannier E et al. Human babesiosis. Infect Dis Clin North Am 2008;22:469-88.
14A.65 Kuwayama DP et al. Spontaneous splenic rupture caused by Babesia microti infection. Clin Infect
Dis 2008;46:e92-5.
14A.66 Wormser GP et al. The clinical assessment, treatment and prevention of Lyme disease, human granulocytic
anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society
of America. Clin Infect Dis 2006;43:1089-134.
14A.67 Krause PJ. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis
2008;46:370-6.
14A.68 Powell VI et al. Exchange transfusion for malaria and Babesia infection. Transfus Med Rev 2002;16:
239-50.
14A.69 Krause PJ et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 2000;
343:1454-8.
14A.70 Schriefer A et al. Recent developments leading toward a paradigm switch in the diagnostic and therapeutic
approach to human leishmaniasis. Curr Opin Infect Dis 2008;21:483-8.
14A.71 Murray HW et al. Advances in leishmaniasis. Lancet 2005;366:1561-77.
14A.72 Croft SL et al. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006;19:111-26.
14A.73 van Griensven J et al. Combination therapy for visceral leishmaniasis. Lancet Infect Dis 2010;10:
184-94.
14A.74 Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob
Agents Chemother 2001;45:2185-97.
14A.75 Bern C et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis
2006;43:917-24.
14A.76 Sundar S et al. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus
alternate-day infusions. Clin Infect Dis 2007;45:556-61.
14A.77 Sundar S et al. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
Clin Infect Dis 2006;42:608-13.
14A.78 Murray HW. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert
Rev Anti Infect Ther 2004;2:279-92.
14A.79 den Boer M et al. Treatment options for visceral leishmaniasis. Expert Rev Anti Infect Ther 2006;4:
187-97.
14A.80 Olliaro PL et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies
done in India, 1980-2004. Lancet Infect Dis 2005;5:763-74.
14A.81 Antinori S et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008;8:191-9.
14A.82 Murray HW. Kala-azar. Progress against a neglected disease. N Engl J Med 2002;347:1793-4.
14A.83 Davidson RN et al. Short course treatment of visceral leishmaniasis with liposomal amphotericin B.
Clin Infect Dis 1996;22:938-43.
14A.84 Sundar S et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J
Med 2010;362:504-12.
14A.85 Sundar S et al. Short course, low dose amphotericin B lipid complex therapy for visceral leishmaniasis
unresponsive to antimony. Ann Intern Med 1997;127:133-7.
14A.86 di Martino L et al. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr
1997;131:271-7.
14A.87 Syriopoulo V et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean
visceral leishmaniasis. Clin Infect Dis 2003;36:560-6.
14A.88 Jacobs S. An oral drug for leishmaniasis. N Engl J Med 2002;347:1737-8.
14A.89 Sundar S et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46.
14A.90 Sundar S et al. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
Pediatr Infect Dis J 2003;22:434-8.
14A.91 Soto J et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect
Dis 2001;33:e57-61.
14A.92 Lira R et al. Evidence that high incidence of treatment failures in Indian kala-azar is due to the emergence
of antimony resistant strains of Leishmania donovani. J Infect Dis 1999;180:564-7.